AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02170103
Drug: Microbubbles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The agents will be divided into two separate doses (two vials per study), and mixed with approximately 29 milliliters of saline (approximately a 2.0-4.0% infusion). The first dilution will be administered pre PCI therapy, and the second dilution infused immediately post PCI. Since Optison is less stable in saline, an alternative approach will be to give the Optison as intermittent 0.1 milliliter boluses followed by 3-5 saline flushes over 10 seconds. The entire duration of each treatment before PCI will be up to 30 minutes depending on time constraints in getting to the catheterization laboratory, while the duration of treatment immediately after PCI will be 30 minutes.
Trial: NCT02367833
Drug: Contraceptive Vaginal Ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of vaginal ring contraceptive (Nuva Ring) on the GH/IGF-1 axis.
Trial: NCT01469377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied in capsules
Trial: NCT03393988
Drug: Fentanyl infusion
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After induction of general anesthesia; Fentanyl infusion (0.5 µg/kg/hr) will be started (which will be afterwards adjusted intraoperatively according to the hemodynamics and Bispectral Index (BIS) reading).
Trial: NCT02203968
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: Normal saline Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
Trial: NCT00478023
Drug: CG5503 IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg; 4 - 6 hourly; Total 72 hours
Trial: NCT00478023
Drug: CG5503 IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg; 4 -6 hourly; Total 72 hours
Trial: NCT00478023
Drug: CG5503 IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg, 4 - 6 hourly; Total 72 hours
Trial: NCT00478023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 - 6 hourly; Total 72 hours
Trial: NCT02143388
Drug: IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.
Trial: NCT02753504
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04691076
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl is intravenously administrated
Trial: NCT00611026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment will be once daily(QD) for 12 weeks.
Trial: NCT04724109
Drug: Equfina
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equfina oral tablets.
Trial: NCT00251732
Drug: Double dose PPI plus evening placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg. twice daily with a placebo
Trial: NCT03229980
Drug: Cold blood cardioplegia (large volume)
RxNorm normalized name: NEBULIZER,LARGE VOLUME #1770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg
Trial: NCT03229980
Drug: Cold blood cardioplegia (small volume)
RxNorm normalized name: BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg
Trial: NCT03725891
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
Trial: NCT00904592
Drug: Qi ming granula
RxNorm normalized name: Saxifraga granulata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qi ming granula Usage:4.5g，po，tid. duration:12 months/ arise Endpoint Event
Trial: NCT00904592
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: Basic therapy ＆ placebo~1. Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~2. placebo,Usage: 4.5g，po，tid
Trial: NCT01405144
Drug: 5-fluoruracil
RxNorm normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% 5-fluoruracil cream, twice a day, during 3 weeks
Trial: NCT00606593
Drug: ACT-078573 oral capsules at 25 and 100 mg and matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
Trial: NCT00606593
Drug: ACT-078573 and matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
Trial: NCT00986037
Drug: ABT-308
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV doses
Trial: NCT00986037
Drug: ABT-308
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple SC doses x 3
Trial: NCT00986037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose
Trial: NCT00986037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple SC doses x 3
Trial: NCT00973232
Drug: Zaldiar®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaldiar® (325 mg acetaminophen and 37.5 mg tramadol HCl): two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
Trial: NCT00973232
Drug: Ultracet®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
Trial: NCT00973232
Drug: Two tablets of DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl), multiple doses, under both fed and fasting conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of DDS-06C, twice daily at 12-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
Trial: NCT00973232
Drug: Zaldiar®, multiple doses,(fed & fasting):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of Zaldiar®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
Trial: NCT00973232
Drug: Ultracet®, multiple doses, (fed & fasting)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of Ultracet®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
Trial: NCT00656669
Drug: doxorubicin and cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin and cyclophosphamide (Segment 3): Following Segment 2, patients will receive 4 cycles (8 weeks) of neoadjuvant treatment with AC.
Trial: NCT01553708
Drug: Silver zinc sulfadiazine cream
RxNorm normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
Trial: NCT01093235
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01093235
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00888719
Drug: CWP-0403 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
Trial: NCT00888719
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets.~Twice a day, 1 tablet at a time for 12 weeks
Trial: NCT00888719
Drug: CWP-0403 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
Trial: NCT00000596
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02602210
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV bolus of 100 mg hydrocortisone in 50ml NaCl 0.9% (sodium chloride); followed by continuous IV infusion of 200 mg hydrocortisone in 50 ml NaCl 0.9% at a rate of 2 ml/h until the start of day 4.Reduction of infusion rate with 0.5 ml/h/day.
Trial: NCT02602210
Drug: NaCL 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV bolus of 50 ml NaCL 0.9%; followed by continuous IV infusion of NaCL 0.9%
Trial: NCT00000426
Drug: Calcium supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01120964
Drug: Intravenous L-Citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01120964
Drug: Placebo of Intravenous L-Citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of intravenous L-Citrulline given at the same prescribed times as L-Citrullne Drug
Trial: NCT01003769
Drug: R-(-)-Gossypol Acetic Acid
RxNorm normalized name: citronellol acetate, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02066909
Drug: 0.15 mg PF-06649751
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
Trial: NCT02066909
Drug: 0.5 mg PF-06649751
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
Trial: NCT02066909
Drug: 0.5 mg PF-06649751
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.
Trial: NCT02840461
Drug: Placebo/Vehicle cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02066909
Drug: 1.5 mg PF-06649751
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.
Trial: NCT02066909
Drug: 1.5 mg PF-06649751 21 Days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.
Trial: NCT02066909
Drug: 3.0 mg PF-06649751
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.
Trial: NCT02944487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules
Trial: NCT02066909
Drug: 5.0 mg PF-06649751
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.
Trial: NCT02066909
Drug: 8.0 mg PF-06649751
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.
Trial: NCT02687815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
Trial: NCT00802945
Drug: NKTR-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-102 given on a q14 day schedule
Trial: NCT00802945
Drug: NKTR-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-102 given on a q21 day schedule
Trial: NCT04114461
Drug: HL-TOF tab. 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HL-TOF
Trial: NCT04114461
Drug: Xeljanz tab. 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xeljanz
Trial: NCT02357771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Trial: NCT02179580
Drug: Xiang-Sha-Liu-Jun-Zi-Tang
RxNorm normalized name: Calagel Reformulated Jun 2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
Trial: NCT02179580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
Trial: NCT00487461
Drug: Simvastatin 40 mg
RxNorm normalized name: simvastatin 40 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparing two doses of Simvastatin to placebo
Trial: NCT00487461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT00487461
Drug: Simvastatin 80 mg
RxNorm normalized name: simvastatin 80 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparing two doses of Simvastatin to placebo
Trial: NCT04077879
Drug: ASP1617
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04077879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01288885
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01288885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03714152
Drug: ABI-H2158
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg or 25 mg tablets
Trial: NCT03714152
Drug: Placebo for ABI-H2158
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic the ABI-H2158 5 mg or 25 mg tablets
Trial: NCT00171262
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02425852
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine alone versus Azathioprine and IFX
Trial: NCT03066466
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV medication given to prevent graft versus host disease in bone marrow transplant.
Trial: NCT02425852
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02425852
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04125082
Drug: Afrezza Inhalant Product
RxNorm normalized name: Afrezza Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks.
Trial: NCT00251680
Drug: Lipid-lowering therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
Trial: NCT05820880
Drug: Fixed [Per/Ind/Aml]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Dose combination of Perindopril/Indapamide/Amlodipine
Trial: NCT03007225
Drug: TACE with Drug Eluting Beads procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The same was done as cTACE till the super selective catheterization of the feeding artery.~Loading of the beads with Doxorubicin hydrochloride (100-150 mg) was done in vitro an hour before the beginning of catheterization. The loaded beads were then aspirated from the vial into a syringe filled with nonionic contrast medium. Once the feeding artery was identified and catheter was in placement, the loaded beads were infused slowly under fluoroscopic guidance. Two different sizes of DC beads were used, 100-300 μm and 300-500. Starting with the smaller sized beads to occlude the tumoral bed followed by the larger sized one to embolize the proximal vessels. The injection of the loaded beads was performed as selective as possible using either a4F diagnostic catheter (Cobra head catheter; Cordis, USA) or 2.7F microcatheter (Progreat; Terumo, Japan).
Trial: NCT01413204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive Placebo orally for 24 weeks.
Trial: NCT02978781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-217 matching placebo capsules
Trial: NCT01796366
Drug: insulin 338 (GIPET I)
RxNorm normalized name: insulin isophane, human Injectable Suspension [Humulin I]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.
Trial: NCT01796366
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S.c placebo administered in combination with insulin 338
Trial: NCT01796366
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo administered in combination with s.c. insulin glargine
Trial: NCT00521404
Drug: CS-1008 (humanized anti-DR5 antibody)
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.
Trial: NCT00711191
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine 1000 mg/m\^2 intravenous administration \[IV\] q week \[wk\]x3 of 4-week cycles
Trial: NCT00739830
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
Trial: NCT02035267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline placebo for injection.
Trial: NCT01045837
Drug: Prednisolone and Gluten free diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten free diet and Oral Prednisolone in a dose of 1 mg/ kg will be given for a period of 4 weeks, thereafter Gluten free diet alone will be continued
Trial: NCT03038880
Drug: Sham Procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.
Trial: NCT01817803
Drug: furosemide/no spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: furosemide (doubling previous furosemide dose)
Trial: NCT01817803
Drug: metolazone/no spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metolazone (add 2.5mg qod)
Trial: NCT01817803
Drug: furosemid/spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: furosemide (doubling previous furosemide dose)+spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
Trial: NCT01817803
Drug: metolazone/spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metolazone (add 2.5mg qod)+ spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
Trial: NCT02376699
Drug: Intravenous (IV) SEA-CD40
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously; schedule is cohort-specific.
Trial: NCT02376699
Drug: Subcutaneous (SC) SEA-CD40
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given subcutaneously on Day 1 every 3 weeks
Trial: NCT00404222
Drug: Hydrocodone/Acetaminophen Extended-Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets x 1
Trial: NCT00404222
Drug: Hydrocodone/Acetaminophen Immediate Release (NORCO®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet q 4 hours x 3
Trial: NCT00404222
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: q 4 hours x 3
Trial: NCT01672671
Drug: Doxorubicin, Paclitaxel, Cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 25 mg/m2, IV weekly. Number of Cycles: 8 Paclitaxel 100 mg/m2, IV weekly. Number of Cycles: 8. Cisplatin 30 mg/m2, IV weekly. Number of Cycles: 8.
Trial: NCT01730222
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine at 1250 mg/ m2 days 1-28